AstraZeneca company profile

AZN · LSE · GBp

Compare AstraZeneca
13,802.00 GBpChange from previous close: −1.65%Absolute change: −232.00 GBp

Close · November 17, 2026

Company profile

AstraZeneca has 96,100 employees and is headquartered in Cambridge, United Kingdom.

Prescription medicines are the core of the business, covering the discovery, development, manufacture and commercialization of drugs. The portfolio spans oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and treatments for rare diseases, with products such as Tagrisso, Enhertu, Farxiga, Fasenra and Beyfortus. Physicians in primary and specialty care are served through distributors and local representative offices in the United Kingdom, the United States, the rest of Europe, Asia, Africa and Australasia.

In the fiscal year ended December 2025, revenue reached US$58.7 billion, up 8.6% from the previous year, and net profit was US$10.2 billion. The United States accounted for 40.8% of revenue and China for 11.3%. The company employs 96,100 people and is headquartered in Cambridge, United Kingdom. Its shares also trade on the New York Stock Exchange.

Company facts

Industry
Drug Manufacturers - General
Headquarters
1 Francis Crick Avenue, CB2 0AA, Cambridge
Employees
96,100
Chief executive
Pascal Claude Soriot
Founded
1992
Fiscal year
January - December
Listing
AZN · LSE
Indices
FTSE 100
Currency
GBp
ISIN
GB0009895292

AstraZeneca and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
AstraZenecaAZNUnited Kingdom$287.12B96,10025.8%26.6
NovartisNOVNSwitzerland$305.16B75,26734.0%32.6
Roche HoldingROPSwitzerland$387.48B103,24933.1%26.7
Novo NordiskNOVO.BDenmark$184.87B68,79450.8%11.2
SanofiSANFrance$116.52B74,84622.3%25.5
GSKGSKUnited Kingdom$102.04B66,84130.5%18.0

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare AstraZeneca with its competitors